Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Hemodynamic Advantage of Dual Perforators in DIEP Flap Reconstruction.

Plastic and reconstructive surgery·2026
Same author

Feasibility of Meta Quest 2 for tracking upper-limb movements under varying field of view conditions: a pilot study.

Scientific reports·2026
Same author

Cannabinoid CB<sub>2</sub> receptor drives trastuzumab resistance and predicts durable anti-HER2 response.

Oncogene·2026
Same author

Identification of key upper-limb muscles during a standardized reach-to-grasp task toward simplified clinical protocols.

Frontiers in bioengineering and biotechnology·2026
Same author

Development of an ELISA as a complement to MAT for swine leptospirosis diagnosis.

Research in veterinary science·2026
Same author

Comparing Outcomes in Microsurgical Reconstruction of Trauma and Burn Patients.

Journal of reconstructive microsurgery·2026

Related Experiment Video

Updated: May 16, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

[Genetic polymorphisms as tool indicators for individual vulnerability to smoking behaviour].

Carme Barrot1, Cristina Sánchez, Rosa Abellana

  • 1Laboratorio de Genética, Unidad de Medicina Legal y Toxicología, Departamento de Salud Pública, Facultad de Medicina, Universidad de Barcelona, Barcelona, España. cbarrotfeixat@ub.edu

Medicina Clinica
|November 27, 2012
PubMed
Summary

Genetic variations in TPH1 may predict smoking cessation success. This study found a trend towards lower TPH1 AA genotype frequency in former smokers, suggesting its role in therapeutic failure.

More Related Videos

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

Related Experiment Videos

Last Updated: May 16, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke
09:50

Impact Assessment of Repeated Exposure of Organotypic 3D Bronchial and Nasal Tissue Culture Models to Whole Cigarette Smoke

Published on: February 12, 2015

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Neurotransmitter pathways are implicated in nicotine dependence.
  • Genetic and pharmacological studies support this role.
  • Four genetic polymorphisms (OPRM1, TPH1, ADRA2A, HTR1B) were investigated.

Purpose of the Study:

  • To compare genotype and allele frequencies of selected polymorphisms in smokers, former smokers, and non-smokers.
  • To identify potential relationships between genetic variations and smoking status.
  • To explore the role of these polymorphisms in nicotine dependence and smoking cessation.

Main Methods:

  • Genotyping of OPRM1, TPH1, ADRA2A, and HTR1B polymorphisms.
  • Comparison of genotype and allele frequencies across three groups: non-smokers, former smokers, and smokers.
  • Statistical analysis of the obtained data.

Main Results:

  • A relationship was observed between sex, age, and the TPH1 locus.
  • A trend indicated a lower frequency of the TPH1 AA genotype in former smokers.
  • No significant associations were found for other investigated polymorphisms.

Conclusions:

  • The TPH1 polymorphism may serve as an indicator of therapeutic failure in smoking cessation.
  • Further research is warranted to elucidate the precise mechanisms linking TPH1 to smoking behavior.